{"component": "contracts", "props": {"contracts": [{"intro": "This Securities Purchase Agreement (this \u201cAgreement\u201d) is dated as of December __, 2019, between Wize Pharma, Inc., a Delaware corporation (the \u201cCompany\u201d), and the purchasers set forth on the signature pages affixed hereto (each, a \u201cPurchaser\u201d and, collectively, the \u201cPurchasers\u201d).", "id": "lVwryRZSCPM", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390019026622/f8k122019ex10-1_wize.htm", "category_name": "Securities Purchase Agreement", "company_name": "Wize Pharma, Inc.", "created": "December 20th, 2019", "published": true, "pretty": null, "uri": "/contracts/lVwryRZSCPM", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "dotagB3PiEn", "group_samples": [{"label": "Securities Purchase Agreement (Wize Pharma, Inc.)", "uri": "/contracts/lVwryRZSCPM", "published": true}, {"label": "Securities Purchase Agreement (Wize Pharma, Inc.)", "uri": "/contracts/dotagB3PiEn", "published": true}], "group_size": 2, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS EMPLOYMENT AGREEMENT (the \u201cAgreement\u201d) is made as of May 22, 2023 by and between Mawson Infrastructure Group, Inc. (the \u201cCompany\u201d) and Rahul Mewawalla (the \u201cExecutive\u201d) (together, the \u201cParties\u201d and each a \u201cParty\u201d).", "id": "kkNNtrKM30z", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390024028158/ea020248101ex10-12_maws.htm", "category_name": "Employment Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "April 1st, 2024", "published": true, "pretty": null, "uri": "/contracts/kkNNtrKM30z", "title": "EMPLOYMENT AGREEMENT", "group_id": "jOsz4S1G9k1", "group_samples": [{"label": "Employment Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/kkNNtrKM30z", "published": true}, {"label": "Employment Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/jOsz4S1G9k1", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Finance services", "type": "industry", "uri": "/contracts/tagged/finance-services"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This Amendment No. 1 (this \u201cAmendment\u201d) to that certain rights agreement (the \u201cRights Agreement\u201d), dated as of February 2, 2026, by and between Big Digital Energy, Inc. (formerly known as Mawson Infrastructure Group Inc., the \u201cCompany\u201d) and Computershare Trust Company, N.A., as Rights Agent (the \u201cRights Agent\u201d), is made and entered into as of June 5, 2026.", "id": "1EdV1P9B89j", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390026089986/ea029997601ex4-2.htm", "category_name": "Rights Agreement", "company_name": "Big Digital Energy, Inc.", "created": "August 14th, 2026", "published": true, "pretty": null, "uri": "/contracts/1EdV1P9B89j", "title": "Amendment No. 1 to Rights Agreement", "group_id": "1EdV1P9B89j", "group_samples": [{"label": "Rights Agreement (Big Digital Energy, Inc.)", "uri": "/contracts/1EdV1P9B89j", "published": true}], "group_size": 1, "tags": [{"name": "Rights Agreement", "type": "category", "uri": "/contracts/tagged/rights-agreement"}, {"name": "Big Digital Energy, Inc.", "type": "company", "uri": "/company/1218683/big-digital-energy-inc"}, {"name": "Finance services", "type": "industry", "uri": "/contracts/tagged/finance-services"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This agreement (the \u201cAmendment\u201d) is entered into on November 8, 2019 (the \"Effective Date\"), by and between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the \"Licensor\") and Wize Pharma Ltd., reg. no. 520033259, the former name of which is Star Night Technologies Ltd. (the \u201cLicensee\u201d) (the Licensor and the Licensee, each a \u201cParty\u201d and shall be collectively referred to hereinafter as the \"Parties\").", "id": "1olqvbBKgJR", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390019023518/f10q0919ex10-2_wizepharma.htm", "category_name": "License Agreement", "company_name": "Wize Pharma, Inc.", "created": "November 14th, 2019", "published": true, "pretty": null, "uri": "/contracts/1olqvbBKgJR", "title": "AMENDMENT TO LICENSE AGREEMENT", "group_id": "1olqvbBKgJR", "group_samples": [{"label": "License Agreement (Wize Pharma, Inc.)", "uri": "/contracts/1olqvbBKgJR", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "2wEoFr8aAoj", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390024028158/ea020248101ex10-17_maws.htm", "category_name": "Service Framework Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "April 1st, 2024", "published": true, "pretty": null, "uri": "/contracts/2wEoFr8aAoj", "title": "SERVICE FRAMEWORK AGREEMENT", "group_id": "2wEoFr8aAoj", "group_samples": [{"label": "Service Framework Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/2wEoFr8aAoj", "published": true}], "group_size": 1, "tags": [{"name": "Service Framework Agreement", "type": "category", "uri": "/contracts/tagged/service-framework-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Finance services", "type": "industry", "uri": "/contracts/tagged/finance-services"}]}, {"intro": "", "id": "33ZnOYt6x26", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-13_ophthalixinc.htm", "category_name": "Licensing Agreement", "company_name": "OphthaliX, Inc.", "created": "July 27th, 2017", "published": true, "pretty": null, "uri": "/contracts/33ZnOYt6x26", "title": "Amendment 2 to Licensing Agreement \u2013 Ukraine Market", "group_id": "33ZnOYt6x26", "group_samples": [{"label": "Licensing Agreement (OphthaliX, Inc.)", "uri": "/contracts/33ZnOYt6x26", "published": true}], "group_size": 1, "tags": [{"name": "Licensing Agreement", "type": "category", "uri": "/contracts/tagged/licensing-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Restated Consulting Services Agreement (the \u201cAgreement\u201d) is entered into on August 20, 2018 and effective as of April 29, 2018 (the \u201cEffective Date\u201d), by and among Wize Pharma Ltd. (Registration Number 520033259), a limited liability company operating under the laws of Israel with offices at Hanagar 24, PO Box 6653 Hod Hasharon, Israel (the \u201cCompany\u201d) and N. Danenberg Holdings (2000) Ltd. (Registration Number 512950981), a limited liability company operating under the laws of Israel having its principal place of business at Borochov 4, Hod- Hasharon, (the \u201cConsulting Company\u201d) through Noam Danenberg I.D. 27868272, an individual residing at Borochov 4, Hod Hasharon (\u201cMr. Danenberg\u201d). The Company, Consultant and Mr. Danenberg are hereinafter referred to collectively as the \u201cparties\u201d and individually as a \u201cparty\u201d.", "id": "3DWczgWGbKo", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390018011573/f8k082018ex10-2_wize.htm", "category_name": "Consulting Services Agreement", "company_name": "Wize Pharma, Inc.", "created": "August 22nd, 2018", "published": true, "pretty": null, "uri": "/contracts/3DWczgWGbKo", "title": "RESTATED CONSULTING SERVICES AGREEMENT", "group_id": "3DWczgWGbKo", "group_samples": [{"label": "Consulting Services Agreement (Wize Pharma, Inc.)", "uri": "/contracts/3DWczgWGbKo", "published": true}], "group_size": 1, "tags": [{"name": "Consulting Services Agreement", "type": "category", "uri": "/contracts/tagged/consulting-services-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS CHAIRMAN AGREEMENT (\u201cAgreement\u201d) is entered into between Wize Pharma, Inc., a Delaware corporation (the \u201cCompany\u201d), and Mark Sieczkarek (\u201cMr. Sieczkarek\u201d) as of April 23, 2019 to be effective on April 23, 2019 (the \u201cEffective Date\u201d). WHEREAS, the Company wishes to engage the services of Mr. Sieczkarek, and Mr. Sieczkarek wishes to accept such an engagement with the Company, on the terms and conditions set forth herein;", "id": "3NIRiOhWgzn", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390019007317/f8k042319ex10-1_wizepharma.htm", "category_name": "Chairman Agreement", "company_name": "Wize Pharma, Inc.", "created": "April 29th, 2019", "published": true, "pretty": null, "uri": "/contracts/3NIRiOhWgzn", "title": "CHAIRMAN AGREEMENT", "group_id": "3NIRiOhWgzn", "group_samples": [{"label": "Chairman Agreement (Wize Pharma, Inc.)", "uri": "/contracts/3NIRiOhWgzn", "published": true}], "group_size": 1, "tags": [{"name": "Chairman Agreement", "type": "category", "uri": "/contracts/tagged/chairman-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Share Purchase Agreement(this\"Agreement\") is made and entered into as of June 18,2015, by and between Mr. Dan Oz (the \u201cFounder\u201d) founder and shareholder ofImproved Vision Systems (I.V.S) Ltd., a company incorporated under the laws of the State of Israel (the \"Company\"), all other shareholders of the Company (the \u201cOther Shareholders\u201d together with the Founder, each listed on Schedule A hereto, the \"Sellers\"),and OphthaliX Inc., a corporation incorporated under the laws of the State of Delaware, or any subsidiary thereof (\u201cOphthaliX\u201d or the \u201cPurchaser\u201d). Each of the Sellers and the Purchaser shall sometimes be referred to as a \"Party\" and together, as the \"Parties\".", "id": "3OETSVo7jHI", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390015004576/f8k061815ex2i_ophthalix.htm", "category_name": "Share Purchase Agreement", "company_name": "OphthaliX, Inc.", "created": "June 19th, 2015", "published": true, "pretty": null, "uri": "/contracts/3OETSVo7jHI", "title": "SHARE PURCHASE AGREEMENT", "group_id": "3OETSVo7jHI", "group_samples": [{"label": "Share Purchase Agreement (OphthaliX, Inc.)", "uri": "/contracts/3OETSVo7jHI", "published": true}], "group_size": 1, "tags": [{"name": "Share Purchase Agreement", "type": "category", "uri": "/contracts/tagged/share-purchase-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Share Purchase Agreement (this \u201cAgreement\u201d) is made and entered into as of the 9 day of January, 2020, by and between Bonus BioGroup Ltd., an Israeli Public Company 520039777 (the \u201cCompany\u201d) and Wize Pharma Inc., a Delaware corporation (the \u201cInvestor\u201d or \u201cWize\u201d).", "id": "4EIQmFK8XFy", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390020001099/f8k010920ex10-2_wizepharma.htm", "category_name": "Share Purchase Agreement", "company_name": "Wize Pharma, Inc.", "created": "January 15th, 2020", "published": true, "pretty": null, "uri": "/contracts/4EIQmFK8XFy", "title": "SHARE PURCHASE AGREEMENT", "group_id": "4EIQmFK8XFy", "group_samples": [{"label": "Share Purchase Agreement (Wize Pharma, Inc.)", "uri": "/contracts/4EIQmFK8XFy", "published": true}], "group_size": 1, "tags": [{"name": "Share Purchase Agreement", "type": "category", "uri": "/contracts/tagged/share-purchase-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This AGREEMENT AND PLAN OF MERGER (the \u201cAgreement\u201d), dated as of the 24th day of February, 2012 is made by and between OphthaliX Inc., a Nevada corporation (\u201cOphthaliX-NV\u201d) and OphthaliX Inc., a Delaware corporation (\u201cOphthaliX-DE\u201d also known as the \u201cSurviving Entity\u201d).", "id": "4MPabGflRTD", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000107878212000959/f8k040512_ex2z1.htm", "category_name": "Merger Agreement", "company_name": "OphthaliX, Inc.", "created": "April 5th, 2012", "published": true, "pretty": null, "uri": "/contracts/4MPabGflRTD", "title": "AGREEMENT AND PLAN OF MERGER BETWEEN OPHTHALIX INC. A NEVADA CORPORATION AND OPHTHALIX INC. A DELAWARE CORPORATION", "group_id": "4MPabGflRTD", "group_samples": [{"label": "Merger Agreement (OphthaliX, Inc.)", "uri": "/contracts/4MPabGflRTD", "published": true}], "group_size": 1, "tags": [{"name": "Merger Agreement", "type": "category", "uri": "/contracts/tagged/merger-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Concrete products, except block & brick", "type": "industry", "uri": "/contracts/tagged/concrete-products-except-block-brick"}]}, {"intro": "Amendment No. 1 (the \u201cAmendment No. 1\u201d), dated as of September 15, 2008, to the Letter of Intent, dated as of July 23, 2008, entered into by and among Denali Concrete Management Inc., a Nevada corporation (\u201cDenali\u201d), and ZZPartners, Inc., a Nevada corporation (\u201cZZP\u201d).", "id": "4UNDvvK2vtz", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000104910708000044/dcmi8kex10_1.htm", "category_name": "Letter of Intent", "company_name": "Denali Concrete Management Inc", "created": "September 16th, 2008", "published": true, "pretty": null, "uri": "/contracts/4UNDvvK2vtz", "title": "AMENDMENT NO. 1 TO THE LETTER OF INTENT", "group_id": "4UNDvvK2vtz", "group_samples": [{"label": "Letter of Intent (Denali Concrete Management Inc)", "uri": "/contracts/4UNDvvK2vtz", "published": true}], "group_size": 1, "tags": [{"name": "Letter of Intent", "type": "category", "uri": "/contracts/tagged/letter-of-intent"}, {"name": "Denali Concrete Management Inc", "type": "company", "uri": "/company/1218683/denali-concrete-management-inc"}, {"name": "Concrete products, except block & brick", "type": "industry", "uri": "/contracts/tagged/concrete-products-except-block-brick"}]}, {"intro": "This memorandum of understanding (this \u201cMOU\u201d) is entered on February 24, 2019 and is intended to reflect our mutual agreement between Resdevco, Research and Development Ltd. (Private Company 510422223, hereinafter \u201cResdevco\u201d) to Wize Pharma Ltd. of Hanagar Hod Hasharon, Israel (\u201cWize\u201d).", "id": "4Z56f5Bi2AS", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390019005537/f10k2018ex10-57_wizepharma.htm", "category_name": "Memorandum of Understanding", "company_name": "Wize Pharma, Inc.", "created": "April 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/4Z56f5Bi2AS", "title": "Memorandum Of Understandings", "group_id": "4Z56f5Bi2AS", "group_samples": [{"label": "Memorandum of Understanding (Wize Pharma, Inc.)", "uri": "/contracts/4Z56f5Bi2AS", "published": true}], "group_size": 1, "tags": [{"name": "Memorandum of Understanding", "type": "category", "uri": "/contracts/tagged/memorandum-of-understanding"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Employment Agreement (\u201cAgreement\u201d) is made and entered into as of August 9, 2021, by and between Mawson Infrastructure Group Inc. (\u201cCompany\u201d) and Liam Daniel Wilson (\u201cEmployee\u201d). As used herein, Company and Employee shall be referred to individually as \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "4hvuvIq3jjg", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390021041756/ea145489ex10-1_mawson.htm", "category_name": "Employment Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "August 12th, 2021", "published": true, "pretty": null, "uri": "/contracts/4hvuvIq3jjg", "title": "EMPLOYMENT AGREEMENT", "group_id": "4hvuvIq3jjg", "group_samples": [{"label": "Employment Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/4hvuvIq3jjg", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Services-computer processing & data preparation", "type": "industry", "uri": "/contracts/tagged/services-computer-processing-data-preparation"}, {"name": "Georgia", "type": "jurisdiction", "uri": "/contracts/tagged/georgia-us"}]}, {"intro": "THIS AMENDMENT TO SHARE PURCHASE AGREEMENT (this \u201cAmendment\u201d), is made and entered into as of August 14, 2015,by and between Mr. Dan Oz (the \u201cFounder\u201d) founder and shareholder of Improved Vision Systems (I.V.S) Ltd., a company incorporated under the laws of the State of Israel (the \u201cCompany\u201d), all other shareholders of the Company (the \u201cOther Shareholders\u201d together with the Founder, each listed on Schedule A attached to the SPA (as defined below), the \u201cSellers\u201d), and OphthaliX Inc., a corporation incorporated under the laws of the State of Delaware, or any subsidiary thereof (\u201cOphthaliX\u201d or the \u201cPurchaser\u201d). Each of the Sellers and the Purchaser shall sometimes be referred to as a \u201cParty\u201d and together, as the \u201cParties\u201d.", "id": "4iI9Gs8mp2N", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390015006574/f8k082515ex2i_ophthalixinc.htm", "category_name": "Share Purchase Agreement", "company_name": "OphthaliX, Inc.", "created": "August 27th, 2015", "published": true, "pretty": null, "uri": "/contracts/4iI9Gs8mp2N", "title": "AMENDMENT TO SHARE PURCHASE AGREEMENT", "group_id": "4iI9Gs8mp2N", "group_samples": [{"label": "Share Purchase Agreement (OphthaliX, Inc.)", "uri": "/contracts/4iI9Gs8mp2N", "published": true}], "group_size": 1, "tags": [{"name": "Share Purchase Agreement", "type": "category", "uri": "/contracts/tagged/share-purchase-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS LEASE AGREEMENT (\u201cLease\u201d) is made as of September 20, 2021 (the \u201cEffective Date\u201d) by and between Jewel Acquisition, LLC, having an address of Six PPG Place, 10th Floor, Pittsburgh, PA 15222 (\u201cLandlord\u201d), and Mawson Infrastructure Group having an address of Level 5, 97 Pacific Highway, North Sydney, NSW 2060, Australia (\u201cTenant\u201d).", "id": "4xkbIIbIeYa", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390021048983/ea147733ex10-1_mawsoninfra.htm", "category_name": "Lease Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "September 21st, 2021", "published": true, "pretty": null, "uri": "/contracts/4xkbIIbIeYa", "title": "LEASE AGREEMENT", "group_id": "4xkbIIbIeYa", "group_samples": [{"label": "Lease Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/4xkbIIbIeYa", "published": true}], "group_size": 1, "tags": [{"name": "Lease Agreement", "type": "category", "uri": "/contracts/tagged/lease-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Services-computer processing & data preparation", "type": "industry", "uri": "/contracts/tagged/services-computer-processing-data-preparation"}]}, {"intro": "This Rights Agreement (this \u201cAgreement\u201d) is dated as of February 2, 2026, by and between MAWSON INFRASTRUCTURE GROUP Inc., a Delaware corporation (the \u201cCompany\u201d), and Computershare Trust Company, N.A., a federally chartered trust company, as rights agent (the \u201cRights Agent\u201d). Each of the Company and the Rights Agent are sometimes referred to herein as a \u201cParty\u201d and collectively as the \u201cParties\u201d. All capitalized terms used in this Agreement have the meanings given to them in \u200eSection 1.", "id": "5AfAnQj2iCD", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390026010845/ea027499701ex4-1_mawson.htm", "category_name": "Rights Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "February 2nd, 2026", "published": true, "pretty": null, "uri": "/contracts/5AfAnQj2iCD", "title": "RIGHTS AGREEMENT", "group_id": "5AfAnQj2iCD", "group_samples": [{"label": "Rights Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/5AfAnQj2iCD", "published": true}], "group_size": 1, "tags": [{"name": "Rights Agreement", "type": "category", "uri": "/contracts/tagged/rights-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Finance services", "type": "industry", "uri": "/contracts/tagged/finance-services"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "And whereas: In the framework of the agreement the parties arranged the legal and commercial relationship between them with respect to the loan (as defined in the agreement);", "id": "5DUNjS8iX81", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-22_ophthalixinc.htm", "category_name": "Convertible Loan Agreement", "company_name": "OphthaliX, Inc.", "created": "July 27th, 2017", "published": true, "pretty": null, "uri": "/contracts/5DUNjS8iX81", "title": "Addendum to the Convertible Loan Agreement of the 20th of March 2016 Which was written and signed on the 30th of March 2016", "group_id": "5DUNjS8iX81", "group_samples": [{"label": "Convertible Loan Agreement (OphthaliX, Inc.)", "uri": "/contracts/5DUNjS8iX81", "published": true}], "group_size": 1, "tags": [{"name": "Convertible Loan Agreement", "type": "category", "uri": "/contracts/tagged/convertible-loan-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Exclusive License Agreement (this \u201cAgreement\u201d) is dated as of September 4, 2019 (the \u201cAgreement Date\u201d) and is entered into by and between Copernicus Therapeutics, Inc., a Delaware corporation (\u201cCopernicus\u201d or \u201cLicensor\u201d), and Wize Pharma, Inc., a Delaware corporation (\u201cWize\u201d or \u201cLicensee\u201d).", "id": "5EfG0fphR56", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390019023518/f10q0919ex10-1_wizepharma.htm", "category_name": "Exclusive License Agreement", "company_name": "Wize Pharma, Inc.", "created": "November 14th, 2019", "published": true, "pretty": null, "uri": "/contracts/5EfG0fphR56", "title": "EXCLUSIVE LICENSE AGREEMENT", "group_id": "5EfG0fphR56", "group_samples": [{"label": "Exclusive License Agreement (Wize Pharma, Inc.)", "uri": "/contracts/5EfG0fphR56", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive License Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-license-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Restated Employment Agreement (this \u201cAgreement\u201d) is entered into on August 22, 2018 and effective as of April 1, 2018 (the \u201cEffective Date\u201d), by and between Wize Pharma Ltd. (Registration Number 520033259) (the \u201cCompany\u201d), a limited company duly registered under the laws of Israel and having its corporate offices located at 24 Hanagar Street, PO Box 6653, Hod Hasharon, Israel, and Or Eisenberg (ID No. 043367259) (the \u201cExecutive\u201d) of Wissotsky 2 Street, Tel-Aviv, Israel.", "id": "5VGChd0D9OB", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390018011573/f8k082018ex10-1_wize.htm", "category_name": "Employment Agreement", "company_name": "Wize Pharma, Inc.", "created": "August 22nd, 2018", "published": true, "pretty": null, "uri": "/contracts/5VGChd0D9OB", "title": "Restated Employment Agreement", "group_id": "5VGChd0D9OB", "group_samples": [{"label": "Employment Agreement (Wize Pharma, Inc.)", "uri": "/contracts/5VGChd0D9OB", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "The undersigned, __________ (\u201cGuarantor\u201d), is entering into this Irrevocable Guaranty and Undertaking (this \u201cGuaranty\u201d), effective as of ________ [insert date of closing of Merger Agreement] (the \u201cEffective Date\u201d), for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, and agrees with, and irrevocably undertakes to, Rimon Gold Assets Ltd. (\u201cLender\u201d), as follows:", "id": "5fZOY2BjUn4", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-32_ophthalix.htm", "category_name": "Irrevocable Guaranty and Undertaking", "company_name": "OphthaliX, Inc.", "created": "July 27th, 2017", "published": true, "pretty": null, "uri": "/contracts/5fZOY2BjUn4", "title": "IRREVOCABLE GUARANTY AND UNDERTAKING", "group_id": "5fZOY2BjUn4", "group_samples": [{"label": "Irrevocable Guaranty and Undertaking (OphthaliX, Inc.)", "uri": "/contracts/5fZOY2BjUn4", "published": true}], "group_size": 1, "tags": [{"name": "Irrevocable Guaranty and Undertaking", "type": "category", "uri": "/contracts/tagged/irrevocable-guaranty-and-undertaking"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "5jKbX68EN1r", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390021027773/f10q0321ex10-6_mawsoninfra.htm", "category_name": "Equipment Finance and Security Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "May 19th, 2021", "published": true, "pretty": null, "uri": "/contracts/5jKbX68EN1r", "title": "AMENDMENT TO THE EQUIPMENT FINANCE AND SECURITY AGREEMENT DATED", "group_id": "5jKbX68EN1r", "group_samples": [{"label": "Equipment Finance and Security Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/5jKbX68EN1r", "published": true}], "group_size": 1, "tags": [{"name": "Equipment Finance and Security Agreement", "type": "category", "uri": "/contracts/tagged/equipment-finance-and-security-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Services-computer processing & data preparation", "type": "industry", "uri": "/contracts/tagged/services-computer-processing-data-preparation"}]}, {"intro": "This letter is written in connection with the Convertible Loan Agreement between Wize Pharma Ltd (the \u201cCompany\u201d) and Rimon Gold Assets Ltd (\u201cRimon Gold\u201d), dated as of March 20, 2016, as amended (the \u201cFirst Loan Agreement\u201d) and a second Convertible Loan Agreement by and between Ridge Valley Corporation (\u201cRidge\u201d) and other lenders who are the assignees of Ridge (Rimon Gold and Shimshon Fisher), dated as of January 12, 2017 (the \u201cSecond Loan Agreement\u201d). The undersigned, by their signatures on this letter agree (severally not jointly) as follows:", "id": "5oTzl3RDLsm", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017013675/f8k122117ex10-1_wizepharma.htm", "category_name": "Convertible Loan Agreement", "company_name": "Wize Pharma, Inc.", "created": "December 27th, 2017", "published": true, "pretty": null, "uri": "/contracts/5oTzl3RDLsm", "title": "Re: Wize Pharma Ltd \u2013 Amendment to the Loan Agreements", "group_id": "5oTzl3RDLsm", "group_samples": [{"label": "Convertible Loan Agreement (Wize Pharma, Inc.)", "uri": "/contracts/5oTzl3RDLsm", "published": true}], "group_size": 1, "tags": [{"name": "Convertible Loan Agreement", "type": "category", "uri": "/contracts/tagged/convertible-loan-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "RESDEVCO owns and possesses certain valuable intellectual property, Licensed Technology, Patents, Know-how and formulations and information with regard to a Finished Product, all as defined in Appendices and is the sole owner of all rights interest and title in such Lincensed Technology and the Finished Product and its Patents, Knowhow formulations and information. RESDEVCO is entitled to license its Know-how.", "id": "62JICgHLyn9", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-09_ophthalix.htm", "category_name": "Exclusive Distribution and Licensing Agreement", "company_name": "OphthaliX, Inc.", "created": "July 27th, 2017", "published": true, "pretty": null, "uri": "/contracts/62JICgHLyn9", "title": "Exclusive Distribution and Licensing Agreement", "group_id": "62JICgHLyn9", "group_samples": [{"label": "Exclusive Distribution and Licensing Agreement (OphthaliX, Inc.)", "uri": "/contracts/62JICgHLyn9", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive Distribution and Licensing Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-distribution-and-licensing-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "63Z6OtisqrM", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000114420413037883/v349202_ex10-16.htm", "category_name": "Non-Executive Director Agreement", "company_name": "OphthaliX, Inc.", "created": "July 2nd, 2013", "published": true, "pretty": null, "uri": "/contracts/63Z6OtisqrM", "title": "OPHTHALIX INC.", "group_id": "63Z6OtisqrM", "group_samples": [{"label": "Non Executive Director Agreement (OphthaliX, Inc.)", "uri": "/contracts/63Z6OtisqrM", "published": true}], "group_size": 1, "tags": [{"name": "Non-Executive Director Agreement", "type": "category", "uri": "/contracts/tagged/non-executive-director-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Resdevco Ltd. and Wize Pharma Ltd. hereby agree that Wize Pharma\u2019s sole rights to commercialize LO2A in China, as declared in the letter from Resdevco, dated, September 6, 2017, shall be limited to one year if by September 6, 2018, Wize Pharma has not signed a distribution agreement of LO2A eye drops in China.", "id": "6BwDzIuPxi7", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex10-42_wizepharma.htm", "category_name": "Commercialization Rights Agreement", "company_name": "Wize Pharma, Inc.", "created": "November 21st, 2017", "published": true, "pretty": null, "uri": "/contracts/6BwDzIuPxi7", "title": "Commercialization Rights of LO2A in China", "group_id": "6BwDzIuPxi7", "group_samples": [{"label": "Commercialization Rights Agreement (Wize Pharma, Inc.)", "uri": "/contracts/6BwDzIuPxi7", "published": true}], "group_size": 1, "tags": [{"name": "Commercialization Rights Agreement", "type": "category", "uri": "/contracts/tagged/commercialization-rights-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This STOCK PURCHASE AGREEMENT (this \u201cAgreement\u201d) is made as of _______________, 2017 by and between OphthaliX, Inc., a Delaware corporation (the \u201cCompany\u201d) and Can-Fite Biopharma Ltd. (\u201cCan-Fite\u201d).", "id": "6LTlsLy9e0O", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017005592/f8k052117ex10i_ophthalix.htm", "category_name": "Stock Purchase Agreement", "company_name": "OphthaliX, Inc.", "created": "May 22nd, 2017", "published": true, "pretty": null, "uri": "/contracts/6LTlsLy9e0O", "title": "STOCK PURCHASE AGREEMENT", "group_id": "6LTlsLy9e0O", "group_samples": [{"label": "Stock Purchase Agreement (OphthaliX, Inc.)", "uri": "/contracts/6LTlsLy9e0O", "published": true}], "group_size": 1, "tags": [{"name": "Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/stock-purchase-agreement"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Third Amendment (the \u201cThird Amendment\u201d) is entered into on December 26, 2017 (the \u201cEffective Date\u201d), by and between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the \u201cLicensor\u201d) and Wize Pharma Ltd., reg. no. 520033259, the former name of which is Star Night Technologies Ltd. (the \u201cLicensee\u201d) (the Licensor and the Licensee shall be collectively referred to hereinafter as the \u201cParties\u201d).", "id": "6TGGtmlulsx", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390018003682/f10k2017ex10-43_wizepharma.htm", "category_name": "Exclusive Distribution and Licensing Agreement", "company_name": "Wize Pharma, Inc.", "created": "March 29th, 2018", "published": true, "pretty": null, "uri": "/contracts/6TGGtmlulsx", "title": "PORTIONS OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934; [***] DENOTES OMISSIONS", "group_id": "6TGGtmlulsx", "group_samples": [{"label": "Exclusive Distribution and Licensing Agreement (Wize Pharma, Inc.)", "uri": "/contracts/6TGGtmlulsx", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive Distribution and Licensing Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-distribution-and-licensing-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Whereas It has been agreed between the parties that the company will receive the services from the consulting company through Mr Noam Danenberg, I.D. XXXXX, of 4 Borochov Street, Hod Hasharon (\u201cDanenberg\u201d), comprehensive strategic consulting services to the company (\u201cthe services\u201d), on the terms of this agreement;", "id": "6dTVpG2MJak", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-39_ophthalix.htm", "category_name": "Agreement for Provision of Services", "company_name": "OphthaliX, Inc.", "created": "July 27th, 2017", "published": true, "pretty": null, "uri": "/contracts/6dTVpG2MJak", "title": "AGREEMENT FOR PROVISION OF SERVICES Drawn up and signed at Herzliya on the 30th day of September 2015 between", "group_id": "6dTVpG2MJak", "group_samples": [{"label": "Agreement for Provision of Services (OphthaliX, Inc.)", "uri": "/contracts/6dTVpG2MJak", "published": true}], "group_size": 1, "tags": [{"name": "Agreement for Provision of Services", "type": "category", "uri": "/contracts/tagged/agreement-for-provision-of-services"}, {"name": "OphthaliX, Inc.", "type": "company", "uri": "/company/1218683/ophthalix-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Whereas Party B has been granted a license with respect to the Products (as defined below) in the Territory (as defined below), and further, Party A has valuable experience and good reputation in the Territory, and Party B has agreed to appoint Party A as an exclusive distributor of the Products in the Territory, therefore, the Parties have, based on the principle of voluntary, equality, fairness, honesty and good faith, through amicable negotiation, agreed as follows:", "id": "6yl2yRZHcXi", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390018007235/f8k053118ex10-1_wizepharma.htm", "category_name": "Exclusive Distribution Agreement", "company_name": "Wize Pharma, Inc.", "created": "June 5th, 2018", "published": true, "pretty": null, "uri": "/contracts/6yl2yRZHcXi", "title": "PORTIONS OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED", "group_id": "6yl2yRZHcXi", "group_samples": [{"label": "Exclusive Distribution Agreement (Wize Pharma, Inc.)", "uri": "/contracts/6yl2yRZHcXi", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive Distribution Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-distribution-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS FIRST AMENDMENT TO LEASE AGREEMENT AND EXERCISE OF OPTION TO LEASE AN ADDITIONAL FOUR ADJOINING ACRES is dated this 23 day of February, 2021 (the \u201cEffective Date\u201d), hereinafter \u201cAmended Lease\u201d or \u201cAmended Agreement\u201d, made and entered into on the dates as hereinafter set forth below, by and between THE DEVELOPMENT AUTHORITY OF WASHINGTON COUNTY with its principal office and place of business in 603 South Harris St. Sandersville, GA, 31082 Washington County, Georgia, as Party of the First Part, hereinafter called \u201cLANDLORD\u201d, and INNOVATIVE PROPERTY MANAGEMENT, LLC, a North Carolina Limited Liability Company, with its principal office and place of business at 5217 Cottage Bluff Ln., Knightdale, NC, 27545 Wake County, North Carolina, as Party of the Second Part, hereinafter called \u201cTENANT\u201d.", "id": "77Zchj1pGLL", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390021027773/f10q0321ex10-2_mawsoninfra.htm", "category_name": "Lease Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "May 19th, 2021", "published": true, "pretty": null, "uri": "/contracts/77Zchj1pGLL", "title": "FIRST AMENDMENT TO LEASE AGREEMENT AND EXERCISE OF OPTION TO LEASE AN ADDITIONAL FOUR ADJOINING ACRES", "group_id": "77Zchj1pGLL", "group_samples": [{"label": "Lease Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/77Zchj1pGLL", "published": true}], "group_size": 1, "tags": [{"name": "Lease Agreement", "type": "category", "uri": "/contracts/tagged/lease-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Services-computer processing & data preparation", "type": "industry", "uri": "/contracts/tagged/services-computer-processing-data-preparation"}]}, {"intro": "Mawson Infrastructure Group Inc., a corporation organized under the laws of Delaware (the \u201cCompany\u201d), confirms its agreement (this \u201cAgreement\u201d) with H.C. Wainwright & Co., LLC (the \u201cManager\u201d) as follows:", "id": "7DCcE1y3iWA", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390025099694/ea026143601ex1-1_mawson.htm", "category_name": "At the Market Offering Agreement", "company_name": "Mawson Infrastructure Group Inc.", "created": "October 17th, 2025", "published": true, "pretty": null, "uri": "/contracts/7DCcE1y3iWA", "title": "AT THE MARKET OFFERING AGREEMENT", "group_id": "7DCcE1y3iWA", "group_samples": [{"label": "At the Market Offering Agreement (Mawson Infrastructure Group Inc.)", "uri": "/contracts/7DCcE1y3iWA", "published": true}], "group_size": 1, "tags": [{"name": "At the Market Offering Agreement", "type": "category", "uri": "/contracts/tagged/at-the-market-offering-agreement"}, {"name": "Mawson Infrastructure Group Inc.", "type": "company", "uri": "/company/1218683/mawson-infrastructure-group-inc"}, {"name": "Finance services", "type": "industry", "uri": "/contracts/tagged/finance-services"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This memorandum of understanding (this \u201cMOU\u201d) is entered this January 8, 2018 and is intended to reflect our mutual agreement concerning the contemplated assignment of distribution rights and a license from Resdevco Research and Development Ltd. (Private Company 510422223, hereinafter \u201cResdevco\u201d) to Wize Pharma Ltd. of Hanagr 5b Hod Hasharon, Israel (\u201cWize\u201d).", "id": "7LdNhm4VucW", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390018003682/f10k2017ex10-44_wizepharma.htm", "category_name": "Memorandum of Understanding", "company_name": "Wize Pharma, Inc.", "created": "March 29th, 2018", "published": true, "pretty": null, "uri": "/contracts/7LdNhm4VucW", "title": "PORTIONS OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE", "group_id": "7LdNhm4VucW", "group_samples": [{"label": "Memorandum of Understanding (Wize Pharma, Inc.)", "uri": "/contracts/7LdNhm4VucW", "published": true}], "group_size": 1, "tags": [{"name": "Memorandum of Understanding", "type": "category", "uri": "/contracts/tagged/memorandum-of-understanding"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This COMMON STOCK PURCHASE WARRANT (the \u201cWarrant\u201d) certifies that ___________ (including any permitted and registered assigns, the \u201cHolder\u201d), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Wize Pharma, Inc., a Delaware corporation (the \u201cCompany\u201d), up to ___________________shares of Common Stock (as defined below) (the \u201cWarrant Shares\u201d) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect.", "id": "7MiKAB3Jwb4", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390019010026/f8k053119ex10-2_wizepharma.htm", "category_name": "Security Agreement", "company_name": "Wize Pharma, Inc.", "created": "June 4th, 2019", "published": true, "pretty": null, "uri": "/contracts/7MiKAB3Jwb4", "title": "COMMON STOCK PURCHASE WARRANT WIZE PHARMA, INC.", "group_id": "7MiKAB3Jwb4", "group_samples": [{"label": "Security Agreement (Wize Pharma, Inc.)", "uri": "/contracts/7MiKAB3Jwb4", "published": true}], "group_size": 1, "tags": [{"name": "Security Agreement", "type": "category", "uri": "/contracts/tagged/security-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This agreement (the \u201cAmendment\u201d) is entered into on May 4, 2020 (the \u201cEffective Date\u201d), by and between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the \u201cLicensor\u201d) and Wize Pharma Ltd., reg. no. 520033259 and/or OcuWize Ltd. reg.no. 515241511, the former name of which is Star Night Technologies Ltd. (the \u201cLicensee\u201d) (the Licensor and the Licensee shall be collectively referred to hereinafter as the \u201cParties\u201d).", "id": "7QVUGOsGY96", "source_url": "https://www.sec.gov/Archives/edgar/data/1218683/000121390021012577/f10k2020ex10-40_wizepharma.htm", "category_name": "License Agreement", "company_name": "Wize Pharma, Inc.", "created": "March 1st, 2021", "published": true, "pretty": null, "uri": "/contracts/7QVUGOsGY96", "title": "AMENDMENT TO LICENSE AGREEMENT", "group_id": "7QVUGOsGY96", "group_samples": [{"label": "License Agreement (Wize Pharma, Inc.)", "uri": "/contracts/7QVUGOsGY96", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Wize Pharma, Inc.", "type": "company", "uri": "/company/1218683/wize-pharma-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLN1FWVUdPc0dZOTYYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAIKGQoIZ3JvdXBfaWQSDRoLYUU1RnNQc3hlRHUYACAB"}}